References
1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71 (3): 209–49. DOI: https://doi.org/10.3322/caac.21660
2. Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019; 10 (2): 63–89. DOI: https://doi.org/10.14740/wjon1191
3. Bespalov V.G., Murazov Ya.G., Panchenko A.V. Prostate cancer chemoprophylaxis: a review of clinical and preclinical data. Eksperimental’naya i klinicheskaya urologiya [Experimental and Clinical Urology]. 2011; (4): 80–5. (in Russian)
4. Murazov Ya.G., Bespalov V.G. Prevention of prostate cancer. Moscow: De Libri, 2018: 136 p. (in Russian)
5. Lacy J.M., Kyprianou N. A tale of two trials: The impact of 5α-reductase inhibition on prostate cancer (review). Oncol Lett. 2014; 8 (4): 1391–6. DOI: https://doi.org/10.3892/ol.2014.2388
6. Klein E.A., Thompson I.M. Jr, Tangen C.M., Crowley J.J., Lucia M.S., Goodman P.J., et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011; 306 (14): 1549–56. DOI: https://doi.org/10.1001/jama.2011.1437
7. Mokbel K., Wazir U., Mokbel K. Chemoprevention of prostate cancer by natural agents: evidence from molecular and epidemiological studies. Anticancer Res. 2019; 39 (10): 5231–59. DOI: https://doi.org/10.21873/anticanres.13720
8. Bespalov V.G., Murazov Ya.G., Kuzhanov A.A., et al. Model of prostate cancerogenesis. Eksperimental’naya i klinicheskaya urologiya [Experimental and Clinical Urology]. 2013; (1): 14–8. (in Russian)
9. Scolnik M.D., Servadio C., Abramovici A. Comparative study of experimentally induced benign and atypical hyperplasia in the ventral prostate of different rat strains. J Androl. 1994; 15 (4): 287–97.
10. Bosland M.C. Use of animal models in defining efficacy of chemoprevention agents against prostate cancer. Eur Urol. 1999; 35 (5–6): 459–63. DOI: https://doi.org/10.1159/000019879
11. McCormick D.L., Rao K.V., Johnson W.D., Bosland M.C., Lubet R.A., Steele V.E. Null activity of selenium and vitamin E as cancer chemopreventive agents in the rat prostate. Cancer Prev Res (Phila). 2010; 3 (3): 381–92. DOI: https://doi.org/10.1158/1940-6207.CAPR-09-0176
12. Sharmila G., Athirai T., Kiruthiga B., Senthilkumar K., Elumalai P., Arunkumar R., et al. Chemopreventive effect of quercetin in MNU and testosterone induced prostate cancer of Sprague-Dawley rats. Nutr Cancer. 2014; 66 (1): 38–46. DOI: https://doi.org/10.1080/01635581.2014.847967
13. Cantagrel V., Lefeber D.J. From glycosylation disorders to dolichol biosynthesis defects: a new class of metabolic diseases. J Inherit Metab Dis. 2011; 34 (4): 859–67. DOI: https://doi.org/10.1007/s10545-011-9301-0
14. McCormick D.L., Rao K.V., Dooley L., Steele V.E., Lubet R.A., Kelloff G.J., et al. Influence of N-methyl-N-nitrosourea, testosterone, and N-(4-hydroxyphenyl)-all-trans-retinamide on prostate cancer induction in Wistar-Unilever rats. Cancer Res. 1998; 58 (15): 3282–8.
15. Sandhu G.S., Nepple K.G., Tanagho Y.S., Andriole G.L. Prostate cancer chemoprevention. Semin Oncol. 2013; 40 (3): 276–85. DOI: https://doi.org/10.1053/j.seminoncol.2013.04.003
16. Bespalov V.G., Panchenko A.V., Murazov Ya.G., Chepik O.F. Influence of sodium selenite on carcinogenesis of the prostate and other organs induced by methylnitrosourea and testosterone in rats. Voprosy oncologii [Problems in Oncology]. 2011; 57 (4): 486–92. (in Russian)
17. Vyshlov E.V., Tsoy E.I., Sultanov V.S., Trusov V.B., Ryabov V.V. Hypolipidemic and hepatoprotective effects of a polyprenol-containing drug in patients with acute coronary syndrome. Bull Exp Biol Med. 2018; 165 (3): 319–21. DOI: https://doi.org/10.1007/s10517-018-4159-x
18. Wang C.Z., Li W.J., Tao R., Ye J.Z., Zhang H.Y. Antiviral activity of a nanoemulsion of polyprenols from ginkgo leaves against influenza A H3N2 and hepatitis B virus in vitro. Molecules. 2015; 20 (3): 5137–51. DOI: https://doi.org/10.3390/molecules20035137
19. Zhang Q., Huang L., Zhang C., Xie P., Zhang Y., Ding S., et al Synthesis and biological activity of polyprenols. Fitoterapia. 2015; 106: 184–93. DOI: https://doi.org/10.1016/j.fitote.2015.09.008
20. US Food Drug Administration. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Rockville, MD: Food and Drug Administration, 2005. URL: http://www.fda.gov/downloads/drugs/guidances/ucm078932.pdf (date of access July 6, 2005)
21. Wang C.-Z., Shen Z.-B., Zheng G.-Y., Zhang S.-F., Cao Z.-Q., Gao C.-X. Antitumor biological activity of polyprenyl phosphate from leaves of Ginkgo biloba L in vivo and vitro. Linchan Huaxue Yu Gongye (Chemistry Industry of Forest Products). 2006; 26: 13–6. URL: http://www.cifp.ac.cn/EN/Y2006/V26/I3/13
22. Xu H.B., He L., Liu G.Q., Li H.T., Wang C.Z. The reversal of P-glycoprotein-mediated MDR by GP associated with chemotherapeutic drugs. Chin Pharm Bull. 2007; 23: 1207–12.
23. Tao R., Wang C., Lu Y., Zhang C., Zhou H., Chen H., et al. Characterization and cytotoxicity of polyprenol lipid and vitamin E-TPGS hybrid nanoparticles for betulinic acid and low-substituted hydroxyl fullerenol in MHCC97H and L02 cells. Int J Nanomedicine. 2020; 15: 2733–49. DOI: https://doi.org/10.2147/IJN.S249773
24. Sari D.P., Basyuni M., Hasibuan P.A., Sumardi S., Nuryawan A., Wati R. Cytotoxic and antiproliferative activity of polyisoprenoids in seventeen mangroves species against WiDr colon cancer cells. Asian Pac J Cancer Prev. 2018; 19 (12): 3393–400. DOI: https://doi.org/10.31557/APJCP.2018.19.12.3393